Hims & Hers Health (NYSE:HIMS) Rating Increased to Hold at Zacks Research

Zacks Research upgraded shares of Hims & Hers Health (NYSE:HIMS) from a strong sell rating to a hold rating in a research report released on Monday,Zacks.com reports.

Other equities analysts also recently issued reports about the company. Wall Street Zen downgraded Hims & Hers Health from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Truist Financial increased their target price on shares of Hims & Hers Health from $18.00 to $23.00 and gave the company a “hold” rating in a research report on Friday, May 22nd. TD Cowen decreased their target price on shares of Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating for the company in a research report on Friday, March 27th. Leerink Partners raised their price target on shares of Hims & Hers Health from $17.50 to $25.00 and gave the stock a “market perform” rating in a report on Monday, March 16th. Finally, Bank of America boosted their price target on shares of Hims & Hers Health from $36.00 to $37.00 and gave the stock a “neutral” rating in a research report on Thursday, July 9th. Four investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $30.70.

Hims & Hers Health Stock Performance

NYSE HIMS opened at $35.14 on Monday. The company has a market capitalization of $8.13 billion, a price-to-earnings ratio of -390.43, a PEG ratio of 96.75 and a beta of 2.35. The company has a quick ratio of 1.56, a current ratio of 1.69 and a debt-to-equity ratio of 2.18. Hims & Hers Health has a twelve month low of $13.74 and a twelve month high of $70.43. The stock has a fifty day simple moving average of $29.69 and a 200 day simple moving average of $26.34.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, May 11th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.44). Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The company had revenue of $608.10 million for the quarter, compared to analyst estimates of $616.84 million. During the same period in the previous year, the firm posted $0.20 earnings per share. The firm’s quarterly revenue was up 3.8% compared to the same quarter last year. Sell-side analysts expect that Hims & Hers Health will post 0.03 EPS for the current year.

Insider Transactions at Hims & Hers Health

In other news, insider Patrick Harrison Carroll sold 23,726 shares of the stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $35.00, for a total transaction of $830,410.00. Following the transaction, the insider owned 181,861 shares of the company’s stock, valued at $6,365,135. This represents a 11.54% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Oluyemi Okupe sold 7,163 shares of the firm’s stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $36.49, for a total value of $261,377.87. Following the completion of the sale, the chief financial officer owned 284,321 shares of the company’s stock, valued at approximately $10,374,873.29. This represents a 2.46% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 167,161 shares of company stock valued at $5,041,152. 11.76% of the stock is owned by insiders.

Institutional Trading of Hims & Hers Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Handelsbanken Fonder AB boosted its holdings in Hims & Hers Health by 4.0% in the second quarter. Handelsbanken Fonder AB now owns 60,000 shares of the company’s stock worth $2,080,000 after acquiring an additional 2,300 shares in the last quarter. Valeo Financial Advisors LLC acquired a new stake in Hims & Hers Health in the second quarter valued at approximately $225,000. FNY Investment Advisers LLC bought a new stake in shares of Hims & Hers Health during the second quarter valued at approximately $347,000. GAMMA Investing LLC increased its holdings in shares of Hims & Hers Health by 32.0% during the second quarter. GAMMA Investing LLC now owns 4,654 shares of the company’s stock valued at $161,000 after acquiring an additional 1,128 shares in the last quarter. Finally, MassMutual Private Wealth & Trust FSB increased its holdings in shares of Hims & Hers Health by 70.0% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company’s stock valued at $27,000 after acquiring an additional 319 shares in the last quarter. 63.52% of the stock is owned by institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.